Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475394 | 0.83 | POLB (0.44) | RAD52PKMPDE10AJAK2POLB | |
| SCHEMBL20943764 | 0.79 | NLRP3 (0.51) | EGFRMAPK14RAD52PRKAG1PRKAA2 | |
| SCHEMBL20943865 | 0.73 | PRMT5 (0.40) | RAD52MAP4K4TYK2CLK4NLRP3 | |
| SCHEMBL10123198 | 0.71 | POLB (0.45) | PDE10APOLBPARP1 | |
| SCHEMBL14665682 | 0.71 | RAD52 (0.55) | RAD52PRKAG1PRKAA2PRKAB1PKM | |
| SCHEMBL30634388 | 0.71 | KDM4E (0.44) | PARP1 | |
| SCHEMBL20943829 | 0.70 | NLRP3 (0.41) | RAD52MAP4K4MINK1CLK4NLRP3 | |
| SCHEMBL15722032 | 0.70 | PARP1 (0.59) | POLBPARP1TLR7 | |
| SCHEMBL29769683 | 0.70 | PARP1 (0.59) | POLBPARP1TLR7 | |
| SCHEMBL20970194 | 0.70 | NLRP3 (0.42) | RAD52NLRP3PKMDHFRTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | EGFR 4492/4885MAPK14 2332/4885RAD52 4422/4885 |
| US-20200157097-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | EGFR 4492/4885MAPK14 2332/4885RAD52 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.